Latest Commercial Milestones News

Artrya Limited has completed the second tranche of its share placement, raising $14.7 million to advance its AI-powered Salix platform for coronary artery disease detection.

Latitude 66 Limited has completed the sale of its 17.5% interest in the Greater Duchess Joint Venture to Carnaby Resources, transforming its balance sheet to a debt-free position with $6.4 million in cash and shares. Meanwhile, promising exploration results at its Australian gold projects and a new cobalt processing agreement in Finland set the stage for growth.

Noxopharm Limited reports growing interest in its Sofra technology with new research collaborations and a safe, well-tolerated HERACLES trial of SOF-SKN. The company also secures funding extensions to support ongoing development.

Lunnon Metals has completed key de-risking at its Lady Herial gold deposit and executed a pivotal Ore Purchase Agreement with Gold Fields, securing a 70% share of future free cash flow. The company maintains a strong cash position while advancing multiple gold prospects and confirming nickel asset viability.

Starpharma has secured two major partnership agreements with Genentech and Radiopharm Theranostics, unlocking significant upfront payments and milestone potential while advancing its clinical pipeline.

NOVONIX has reached mutual agreement to draw down an additional US$40 million tranche of convertible debentures from Yorkville Advisors, advancing its funding strategy to support growth in battery technology.

Avecho Biotechnology has raised $2.5 million from institutional investors to fast-track manufacturing and regulatory preparations for its CBD TPM capsule amid ongoing Phase III trials.

Lumos Diagnostics reported steady quarterly revenue with a 300% surge in product sales, driven by its flagship FebriDx® test. The company inked a landmark US$317 million exclusive U.S. distribution agreement and awaits FDA feedback on its CLIA waiver application.

Audeara Ltd has reported a remarkable 111% revenue increase in Q1 FY26, driven by strong growth in its technology division and key international partnerships in China and Japan. The company is advancing towards cashflow breakeven with improved cash management and expanding global reach.

VRX Silica Limited has secured four binding offtake contracts for 410,000 tonnes per annum of silica sand from its Arrowsmith North project, representing nearly half of its initial production capacity and marking a significant commercial milestone.

Imricor Medical Systems made significant regulatory strides with FDA submissions for its MRI-guided cardiac ablation devices and launched NorthStar commercially in Europe, even as it reported increased cash outflows in Q3 CY25.

Vitrafy Life Sciences has delivered its first production unit of the next-generation cryopreservation device, advanced its US commercial footprint, and maintained a strong financial position heading into FY2026.